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ABSTRACT
Introduction: Tight glycemic control and
timely treatment can improve outcomes in
patients with diabetes yet many remain
sub-optimally controlled. The objective of the
current study was to evaluate the effect of
switching patients with sub-optimally
controlled diabetes to the V-Go (Valeritas
Inc., Bridgewater, NJ, USA) Disposable Insulin
Delivery device.
Methods: A retrospective analysis of electronic
medical records was conducted to assess
patients with sub-optimal glycemic control
defined as a glycated hemoglobin (HbA1c)
[7%, switched to V-Go. Blood glucose control
defined as change from baseline in HbA1c,
prescribed insulin doses, body weight,
concomitant anti-hyperglycemic agents, and
reported hypoglycemia were collected prior to
switching to V-Go and during V-Go use.
Results: Two-hundred and four patients were
evaluated during the study period. Overall,
there was a significant decrease in HbA1c after
switching to V-Go at the 14- and 27-week
follow-up visits. The least-squares mean (LSM)
change in HbA1c (95% confidence interval)
from baseline to 14 weeks was -1.53%
(-1.69% to -1.37%; P\0.001), and from
baseline to 27 weeks was -1.79% (-1.97% to
-1.61%; P\0.001). Significant reductions in
mean HbA1c were achieved at both visits in all
patient subsets: Patients with type 2 and type
1/latent autoimmune diabetes in adults (LADA);
patients using insulin at baseline and patients
naı¨ve to insulin at baseline. Patients
administering insulin at baseline required
significantly less insulin on V-Go (86–99 LSM
units/day at baseline to 58 LSM units/day at
27 weeks; P\0.001). Across all patients,
reported hypoglycemic events were no more
frequent on V-Go than on previous therapy.
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Conclusion: V-Go is safe and effective in
patients with sub-optimally controlled diabetes
requiring insulin therapy. Glycemic control
improved significantly, less insulin was
required, and hypoglycemic events were
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INTRODUCTION
Diabetes mellitus is a prevalent disease on the
rise with serious impact on healthcare costs and
patient safety. In the United States alone there
are 29.1 million patients with diabetes,
including 8.1 million undiagnosed cases [1].
The majority are patients diagnosed with
type 2 diabetes, and approximately
1.25 million patients are diagnosed with type 1
diabetes [1]. Long-term complications of
diabetes include microvascular complications,
stroke, kidney disease, blindness, and
neuropathy and it is well established that tight
glycemic control and timely treatment improve
outcomes and reduce complications [2, 3].
Patients with type 1 diabetes require
continuous insulin infusion or multiple daily
injections (MDI) of insulin. Due to the decline
of islet cell function over time it is likely that
many patients with type 2 diabetes will
eventually require insulin therapy as treatment
is progressed.
In type 2 diabetes, insulin therapy is
typically initiated with a single injection of
basal insulin, and if targets are not met after
active titration patients may be progressed to a
basal-bolus regimen with MDI. Basal insulin
therapy is sufficient for many patients;
however, despite optimization of basal insulin
evidence suggests\40% of patients with type 2
diabetes achieve glycemic targets [3]. In the
Treating to Target in Type 2 diabetes study
(ClinicalTrials.gov identifier, NCT00184600),
most patients (82%) required insulin
intensification to include mealtime bolus
insulin by 3 years to achieve glycemic targets
[4].
Increased complexity of treatment regimens
leads to decreased adherence, which in turn
impacts efficacy [5–7]. Insulin non-adherence
has been correlated with patient perceptions of
regimen inflexibility and the burden on one’s
lifestyle [8]. Surprisingly, 72% of patients on
MDI therapy report they never take injections
outside of the home [9]. Addressing these
treatment barriers may improve patient
outcomes.
V-Go (Valeritas, Inc., Bridgewater, NJ, USA),
shown in Fig. 1, is a disposable, wearable insulin
delivery device that delivers a continuous basal
rate of insulin, as well as on-demand mealtime
dosing. V-Go is available in basal rates of 20, 30,
or 40 units/24 h and can administer up to an
additional 36 units of insulin for mealtime
bolus dosing in 2 unit increments. V-Go is
Fig. 1 V-Go Disposable Insulin Delivery device
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filled with U-100 fast-acting insulin (insulin
lispro, rDNA origin or insulin aspart, rDNA
origin have been tested by Valeritas and found
safe for use in V-Go) [10] and is affixed to the
skin. The push of a button inserts a 4.6 mm
30 gauge stainless steel needle subcutaneously,
which initiates delivery of a continuous preset
basal rate of insulin. Patients can self-administer
mealtime bolus doses by pressing the bolus
ready button and the bolus delivery button
through clothing for discreet insulin
administration. V-Go uses a hypoallergenic
and latex-free adhesive to adhere to the skin,
and is designed to be removed and replaced
every 24 h.
Use of V-Go has been associated with
improved glycemic control [11–13]. An
investigation done by Rosenfeld and
colleagues showed a decrease in glycated
hemoglobin (HbA1c) when patients were
switched to insulin delivery by V-Go, and an
increase in HBA1c following the cessation of
V-Go [11]. The current study examined
real-world use of V-Go in a specialized diabetes
system. The purpose of this study was to
evaluate glycemic control after patients with
sub-optimally controlled diabetes on previous
therapeutic regimens were switched to insulin
therapy delivered by V-Go.
METHODS
Study Design and Criteria
The study was conducted as a retrospective
review of the electronic medical record (EMR)
database for Diabetes America, a specialized
diabetes comprehensive care clinic setting
which includes 13 centers located across major
metropolitan areas of Texas. Patients were
prescribed V-Go by health care providers as
part of their standard clinical practice with the
goal of improving HbA1c levels. Baseline
insulin doses, HbA1c, changes to concomitant
medications, and weight were all factors
considered by clinicians when determining the
starting V-Go dose. Additionally, it was taken
into consideration that delivering insulin via
continuous subcutaneous infusion has been
shown to typically reduce insulin
requirements by 20–30% [14, 15]. Patient
education and support included basic
instruction on the use of V-Go by a member
of the health care team and supportive written
materials as well as access to a 24 h customer
care center were provided by the manufacturer
as is routine for all patients initiated on V-Go.
Patients were managed per clinician standard of
care including timing and frequency of
follow-up visits and medication management.
A systematic search using keywords identified
potential patients switched to V-Go between
April 1, 2013 and October 3, 2014 and patient
charts were then reviewed against study
inclusion and exclusion criteria to determine
study eligibility. Inclusion criteria required (1)
patients diagnosed with diabetes mellitus
(type 1, type 2, or LADA); (2) age equal to or
[21 years; (3) baseline HbA1c between 7% and
14% (within 6 weeks of V-Go initiation); (4)
previously prescribed basal or basal-bolus
insulin therapy or naı¨ve to insulin therapy,
with or without anti-hyperglycemic
medications; and switched to insulin delivery
by V-Go; and (5) a minimum of one subsequent
HbA1c lab value on V-Go. Patients were
excluded for (1) history of treatment with
U-500 insulin preceding V-Go initiation or the
non-Food and Drug Administration approved
utilization of U-500 insulin delivery by V-Go;
(2) receiving insulin delivery via an insulin
pump immediately preceding V-Go initiation;
(3) pregnancy or lactation; (4) undeterminable
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insulin dosing due to insufficient
chart information; or (5) a history of
pancreatic cancer.
The primary endpoint in the study was
change in HbA1c from baseline. Secondary
endpoints evaluated in the study included
insulin dose, body weight, and hypoglycemic
events. The study protocol was reviewed and
approved by Allendale investigational review
board, and a waiver of informed consent was
approved.
Data Collection
Clinical and demographic data were extracted
from the EMR at baseline and for all subsequent
office visits when an HbA1c value was captured
and the patient remained on V-Go. Clinical
data extracted included HbA1c values, fasting
plasma glucose levels, prescribed and patient
reported insulin use, body weight, concomitant
anti-hyperglycemic medications, and
patient-reported hypoglycemic events. It is
common to prescribe insulin dosing as a
range, with a lower limit representing the
primary dose excluding titration and
correction, and the upper limit allowing
additional units to optimize insulin therapy
(titration, correction, sliding scale). Both the
lower and upper limits of the prescribed
baseline insulin use were collected in the
study. Patient-reported insulin dosing was also
captured when available for comparison to
actual prescribed doses.
Concomitant anti-hyperglycemic
medications were recorded at baseline and at
each follow-up visit. Patients were categorized
as having an increase, decrease or no change to
baseline concomitant medications at the
follow-up visit. An addition or removal of a
medication, as well as a change in dose with a
proven difference in efficacy over the previous
dose qualified as a change in concomitant
medications. The time course of the change in
medications relative to the follow-up visit was
also reviewed during the data collection process
to assess whether adequate time had elapsed for
any therapeutic benefit of the medication
change to take effect. It was confirmed that in
90% of patients categorized as having a change
in concomitant medications, at least 2 months
had elapsed from the time of the change to the
time of the follow-up HbA1c value, so any
impact of the concomitant medication change
would be reflected in the follow-up HbA1c
value.
The principal investigator oversaw review of
subject records to determine study eligibility,
and data collection. Records from all sites were
reviewed via the EMR database in Plano, Texas.
Clinical results on V-Go were collected through
March 31, 2015 for inclusion in the current
study analysis.
Statistical Analysis
Independent statistical analyses were performed
by the Department of Mathematics and
Statistics at the University of Central
Oklahoma. A one-factor repeated measures
analysis of covariance (ANCOVA) model
including a factor for time period and the
baseline measurement as the covariate was
performed to test for the differences from
baseline for HbA1c, insulin dosage, and
weight. The influence of baseline HbA1c on
change in HbA1c was analyzed using a
two-factor repeated measures analysis of
variance (ANOVA) including factors for time
period, baseline HbA1c range (7.1–8.9%,
9.0–10.4%, 10.5–13.9%), and interaction
between the two factors. To test for differences
in the mean weight (kg), total daily dose (TDD)
of insulin, and HbA1c from baseline to week 14
534 Diabetes Ther (2015) 6:531–545
on V-Go among those with either an increase,
decrease, or no change to concomitant
medications, a two-factor repeated measures
ANOVA was performed for each variable with
factors for time period, change in concomitant
meds, and interaction between the two factors.
For all of the tests, a spatial power covariance
structure was modeled to adjust for the
differences in the number of days between
time periods. Changes from baseline for all
analyses are expressed as least-squares means
(LSM) with 2-sided 95% confidence intervals
(CIs) unless otherwise noted.
If any ANOVA or ANCOVA resulted in a
significant P value (P\0.05) the analysis was
followed by pairwise comparisons using Tukey’s
adjustment for multiplicity. All tests were
performed using proc mixed in SAS v.9.3 (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Study Population
A database query identified 245 eligible patients
based on inclusion criteria, of which 204 were
included in the analysis. Prior use of U-500
regular insulin and undeterminable insulin
dosing were the leading reasons for exclusion.
All patients had one follow-up HbA1c result per
protocol inclusion criteria and a second
follow-up HbA1c result was available during
the analysis period for 137 patients. The mean
time from start of V-Go to the first follow-up
visit was 13.87 ± 6.14 weeks and the mean time
to the second follow-up visit was
26.86 ± 8.96 weeks. Results will therefore be
presented for 14- and 27-week visits.
One-hundred and seventy-five patients were
diagnosed with type 2 diabetes and 29 patients
with type 1 diabetes or LADA. The majority of
patients (n = 180) were using insulin at baseline
and 24 patients were naı¨ve to insulin at
baseline. Patient characteristics are shown in
Tables 1 and 2. The TDD of insulin was greater
in patients with type 2 diabetes than in patients
with type 1 diabetes or LADA. Patient-reported
baseline TDD was 10% lower than the lower
limit and 22% lower than the upper limit of the
prescribed insulin dose range. At baseline, the
majority of patients (66%) were taking
concomitant anti-hyperglycemic medications
with 53% of patients included in the study
having already escalated treatment to two or
more agents. As is to be expected in a
comprehensive system where patients are
referred for treatment, comorbidities were
common with a majority of patients also
diagnosed with hypertension (83%) and
hyperlipidemia (69%).
Glycemic Response to V-Go
Overall, there was a significant decrease in
HbA1c after switching to V-Go across all
patient types. The HbA1c LSM change for the
overall patient population and by types of
diabetes is displayed in Fig. 2. HbA1c results
were also analyzed by use of insulin at baseline
prior to switching to V-Go. In patients
administering insulin at baseline, the
reduction in mean HbA1c from baseline to
14 weeks was -1.34% (-1.51% to -1.18%;
P\0.001) and from baseline to 27 weeks was
-1.58% (-1.77% to -1.39%; P\0.001).
Patients naı¨ve to insulin prior to baseline
experienced the most substantial decrease in
mean HbA1c after switching to V-Go, with a
reduction in mean HbA1c from baseline to
14 weeks of -2.97% (-3.56% to -2.38%;
P\0.001) and a reduction from baseline to
27 weeks of -3.44% (-4.12% to -2.75%;
P\0.001).
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Female 116 (57) 100 (57) 16 (55) 100 (56) 16 (67)
Male 88 (43) 75 (43) 13 (45) 80 (44) 8 (33)
Age (years) 53 ± 13 55 ± 12 43 ± 13 54 ± 12 47 ± 13
Range 21–88 21–88 23–65 23–88 21–69
Race
Caucasian 142 (69) 121 (69) 21 (72) 126 (70) 16 (67)
African American 44 (22) 38 (22) 6 (21) 42 (23) 2 (8)
Undetermined 18 (9) 16 (9) 2 (7) 12 (7) 6 (25)
Ethnicity: Hispanic 32 (16) 30 (17) 2 (7) 26 (14) 6 (25)
Duration of diabetes (years) 13.7 ± 8.4 13.2 ± 7.5 17.0 ± 12.4 14.5 ± 8.3 8.0 ± 6.7
Range 0.1–53 0.1–36 1.0–53 0.5–53 0.1–29
Weight (kg) 96.6 ± 21.1 98.0 ± 20.5 88.6 ± 23.2 97.1 ± 21.2 93.3 ± 20.1
Range 52.7–160.5 54.6–160.5 52.7–148.6 52.7–160.5 54.5–130.5
BMI (km/m2) 34.13 ± 7.43 34.62 ± 7.41 31.13 ± 6.95 34.28 ± 7.56 33.00 ± 6.44
HbA1c (%)
Mean ± SD 9.63 ± 1.59 9.65 ± 1.62 9.48 ± 1.44 9.41 ± 1.46 11.28 ± 1.63
C7% to\9.0% 80 (39) 68 (39) 12 (41) 78 (43) 2 (8)
C9.0% to\10.5% 62 (30) 52 (30) 10 (34) 56 (31) 6 (25)
C10.5% to\14.0% 62 (30) 55 (31) 7 (24) 46 (26) 16 (67)
FPG (mg/dL) 201 ± 73 196 ± 70 248 ± 89 197 ± 71 238 ± 82
Comorbidities
Hypertension 169 (83) 153 (87) 16 (55) 153 (85) 16 (67)
Hyperlipidemia 140 (69) 120 (69) 20 (69) 119 (66) 21 (88)
Renal disease 21 (10) 18 (10) 3 (10) 19 (11) 2 (8)
Coronary artery disease 27 (13) 26 (15) 1 (3) 25 (14) 2 (8)
Retinopathy 33 (16) 26 (15) 7 (24) 28 (16) 5 (21)
Neuropathy 48 (24) 43 (25) 5 (17) 42 (23) 6 (25)
Data are n (%) or mean ± SD
BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, LADA latent autoimmune diabetes in
adults
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The blood glucose response was evaluated
stratifying baseline HbA1c by tertile to
determine if baseline HbA1c impacted the
level of glycemic change (Fig. 3). Significant
and progressive reductions in HbA1c were seen
in all three subsets at both the 14-week and
27-week timepoints (P\0.001).
The distribution of HbA1c values for the
study population at baseline was compared to
the distribution at both follow-up HbA1c time
points. Figure 4 plots the distribution of HbA1c
values and presents overall arithmetic mean
values at baseline, 14, and 27 weeks. On V-Go,
the HbA1c distribution curve has narrowed and
progressively shifted to the left, representing a
reduction in variability and lower HbA1c
values.
Insulin Dose on V-Go
Prescribed daily basal insulin and TDD at V-Go
initiation, 14, and 27 weeks were analyzed after
switching to V-Go for those patients
administering insulin prior to V-Go (Fig. 5).
For both TDD and basal insulin doses, there
were statistically significant reductions in
insulin requirements after switching to V-Go
(P\0.001). At 27 weeks, TDD on V-Go was 33%
lower than the lower limit and 41% lower than
the upper limit of the prescribed baseline dose
range. Basal insulin rates were 39% lower than
the lower limit and 46% lower than the upper
limit of the prescribed baseline dose range. The
mean daily insulin dose administered with
V-Go at week 27 was 0.6 ± 0.19 units/kg/day.
At both follow-up visits only 8.8% of patients
received supplemental insulin, which was
included in the reported insulin dosage during
V-Go use.
Based on the significant reduction in basal
insulin, a follow-up analysis was conducted to
evaluate if the reduction in basal insulin dose
impacted fasting plasma glucose. A paired t test
analysis at 27 weeks demonstrated a significant
reduction (-46 mg/dL from an arithmetic mean
baseline of 182 mg/dL; P\0.001) in a subset of
patients (n = 67) with repeated fasting plasma
glucose measures available in the EMR. This
significant reduction occurred despite a 44%
reduction (61 to 34 units/day; P\0.001) in
basal insulin for this subset.
In patients naı¨ve to insulin at baseline the
mean TDD of insulin was 54 units at 27 weeks.
Of this mean TDD 57% was basal insulin and
43% was mealtime bolus insulin.
Mean insulin dose during V-Go use remained
stable. However, reflected in this relatively
stable mean dose are increases and decreases
in basal and bolus doses by individual patients.
Insulin titrations were analyzed separately for
basal insulin and bolus insulin. The majority of
titration occurred between baseline and
14 weeks. Increases in basal rate occurred in
24% of patients initiated on V-Go 20 or 30, and
decreases in basal rate occurred in 6% of
patients initiated on V-Go 30 or 40. Overall,
nearly half of all patients had a titration in
bolus dose with 27% increasing and 21%
decreasing bolus dose use.
Evaluation of Efficacy Based on Changes
to Concomitant Medications
Changes to concomitant anti-hyperglycemic
medications were reviewed and data was
analyzed to assess whether changes to
concomitant medications may have impacted
study outcomes. One-hundred and ten patients
had no change to concomitant medications,
43 patients had increases, and 39 patients had
decreases in concomitant medications. Twelve
patients implemented multiple changes and
were not able to be categorized. HbA1c, TDD
of insulin, and weight prior to V-Go and at
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14 weeks were compared for patients with
increases, decreases, and no changes to
anti-hyperglycemic concomitant medications
(Table 3).
All three groups experienced a significant
reduction in HbA1c after switching to V-Go
irrespective of changes to concomitant
medications. There was no significant
difference in HbA1c between the groups at
baseline, nor at week 14, confirming that
changes to concomitant medications were not
a factor in the reduction in HbA1c seen with
V-Go use. At baseline, patients with an increase
in concomitant medications had a significantly
higher mean TDD of insulin (P\0.01);
however, there was no significant difference in
mean TDD between any of the groups after
switching to V-Go. Patients with an increase in


















Basal insulin dose (U/day)
Patient reporteda – 53 ± 28 39 ± 17 51 ± 27 –
Lower limit prescribed – 56 ± 31 41 ± 16 54 ± 30 –
Upper limit prescribed – 60 ± 31 49 ± 22 58 ± 30 –
Prescribed range – 12–120 18–100 12–220 –
Insulin TDD (U/day)
Patient reporteda – 78 ± 46 69 ± 31 77 ± 44 –
Lower limit prescribed – 86 ± 50 86 ± 35 86 ± 48 –
Upper limit prescribed – 98 ± 55 104 ± 41 99 ± 53 –
Prescribed range – 16–310 31–180 16–310 –
Concomitant medicationsb
Metformin 89 (44) 80 (46) 9 (31) 77 (43) 12 (50)
Sulfonylurea 43 (21) 40 (23) 3 (10) 34 (19) 9 (38)
GLP-1 receptor agonist 40 (20 37 (21) 3 (10) 38 (21) 2 (8)
DPP-4 inhibitor 18 (9) 18 (10) 0 (0) 16 (9) 2 (8)
DPP-4 I/Metformin 17 (8) 17 (10) 0 (0) 12 (7) 5 (21)
SGLT-2 inhibitor 11 (5) 10 (6) 1 (3) 10 (6) 1 (4)
TZD 8 (4) 8 (5) 0 (0) 8 (4) 0 (0)
Data are n (%) or mean ± SD
DDP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, LADA latent autoimmune diabetes in adults, SGLT-2
sodium-glucose co-transporter-2, TDD total daily dose, TZD thiazolidinedione
a Patient reported mean insulin doses reﬂective for 121, 23, and 142 patients in type 2, type 1/LADA, and insulin cohorts,
respectively
b Concomitant medications prescribed for\2% of population not included. Multiple medications are possible per patient
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Fig. 2 Effects of insulin delivery by V-Go on HbA1c. a All
patients (n = 204), b patients with type 2 diabetes
(n = 175), and c patients with type 1 diabetes or LADA
(n = 29). Change in HbA1c reported as LSM with
corresponding 95% conﬁdence intervals derived from a
repeated measures mixed model for ﬁrst recorded HbA1c
on V-Go (14-week mean) and second recorded HbA1c on
V-Go (27-week mean) from baseline (week 0). Time points
represent the mean time elapsed between V-Go initiation
and follow-up HbA1c for the total population. *P\0.001
compared to baseline. HbA1c glycated hemoglobin, LADA
latent autoimmune diabetes in adults, LSM least-squares
mean
Fig. 3 V-Go glycemic response by baseline HbA1c tertile.
Tertile 1 (n = 80), tertile 2 (n = 62), and tertile 3
(n = 62). Data are LSM change in HbA1c with corre-
sponding 95% conﬁdence interval derived from a repeated
measures mixed model for ﬁrst recorded HbA1c on V-Go
(14-week mean) and second recorded HbA1c on V-Go
(27-week mean) from baseline by tertile. Time points
represent the mean time elapsed between V-Go initiation
and follow-up HbA1c results for the total population.
*P\0.001 compared to baseline. HbA1c glycated hemo-
globin, LSM least-squares mean
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concomitant medications had a significantly
higher mean weight at both baseline and on
V-Go compared to patients with a decrease or
no change in concomitant medications
(P\0.01).
Among all subjects there was a significant
change in weight from baseline with insulin
delivery by V-Go (P\0.001). LSM weight was
96.6, 97.9, and 98.1 kg at baseline and at 14 and
27 weeks after switching to V-Go, respectively.
Hypoglycemia captured from charts was similar
during V-Go use compared to baseline with
rates of 19, 20, and 22% at baseline, 14, and
27 weeks, respectively. One case of severe
hypoglycemia was reported by a patient
administering a basal rate of 20 units per day
with V-Go and no bolus insulin. The patient did
not require third party assistance and continued
to use V-Go. Of the 204 subjects included in the
study, 32 discontinued use of V-Go prior to the
second HbA1c follow-up for reasons including:
skin irritation (9), cost/insurance coverage (7),
transitioned to an insulin pump (5), weight gain
(2), undetermined reason (2), and did not prefer
V-Go, pain, GI effect, hyperglycemia,
hypoglycemia and lack of adherence to skin
(1 each). Patient baseline characteristics were
similar between those that continued therapy
and those that discontinued V-Go.
DISCUSSION
In this study, we examined the outcomes of 204
patients after being switched to insulin therapy
delivered by V-Go. Due to the progressive
nature of diabetes, treatment intensification is
required to maintain acceptable blood glucose
control and decrease the risk of adverse
outcomes. Insulin is the most consistently
effective and potent way to improve blood
glucose control [16, 17]. Guidelines
recommend basal insulin therapy plus
mealtime boluses as a treatment
intensification option delivered by either MDI
or continuous subcutaneous infusion [18]. This
retrospective analysis identified patients from a
specialized comprehensive diabetes care clinic
setting who had not achieved adequate blood
glucose control with their current treatment
regimen and were changed to insulin delivery
with V-Go according to clinician judgment. The
multi-clinic system treats a large number of
patients who are referred from primary care sites
for specialized care, which is reflected in the
mean duration of diabetes of 13.7 years and a
baseline HbA1c of 9.63% in the study
population. After switching to V-Go, glycemic
control improved regardless of patient type,
baseline TDD, HbA1c, or treatment regimen
Fig. 4 Change in HbA1c distribution. HbA1c data are
arithmetic means at baseline (week 0) compared to ﬁrst
recorded HbA1c on V-Go (14-week mean) and second
recorded HbA1c on V-Go (27-week mean). Curves
represent the HbA1c distribution of patients for each
time point based on available data. BL baseline, HbA1c
glycated hemoglobin
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used prior to V-Go, and this improvement was
accomplished with a significantly lower TDD of
insulin. The nearly 1.8% decrease in mean
HbA1c seen after 27 weeks of V-Go use is
clinically meaningful for any diabetic
population, and it is even more significant
considering the study population included
difficult to manage patients referred for
specialized care. The greatest number of
diabetes complications may be avoided by
improving glycemic control in patients with
very poor control [19]. Sixty percent of patients
included in the study had baseline HbA1c
values over 9%, and 30% of patients included
in the study had baseline HbA1c values over
10.5%. Patients in this highest HbA1c subset
over 10.5% had substantial and statistically
significant decreases in HbA1c with reductions
of nearly 3% at 14 weeks and 3.35% at 27 weeks.
As commonly reported for other diabetes
treatments, the higher the baseline HbA1c at
the time of treatment initiation, the greater the
reduction in HbA1c.
Because insulin regimens can impact daily
routines and lifestyles, convenience and ease of
administration are a consideration when
initiating and titrating insulin regimens.
Intensification from basal insulin therapy to
MDI therapy may be delayed due to the
inconvenience of multiple injections and
patients often do not adhere to a MDI regimen
especially when injections are required to be
taken outside the home. Data from this study
for insulin dosing prior to V-Go use support this
lack of adherence; in patients using insulin
prior to V-Go, the patient-reported TDD of
insulin dose was 10% lower than the lower
limit and 22% lower than the upper limit of the
prescribed range, confirming that patients were
using less insulin than prescribed. V-Go may
improve adherence with administering bolus
doses considering insulin is readily available
Fig. 5 Insulin dosage. a Basal insulin dose/rate. b Insulin
TDD. Data reﬂects insulin cohort (n = 180). Insulin data
are LSM with corresponding 95% conﬁdence intervals
derived from a repeated measures mixed model for baseline
upper and lower limit prescribed dose range compared to
V-Go initiation dose, dose at ﬁrst recorded HbA1c on
V-Go (14-week mean), and dose at second recorded HbA1c
on V-Go (27-week mean). *P\0.001 compared to baseline
lower limit prescribed dose. HbA1c glycated hemoglobin,
LSM least-squares mean, TDD total daily dose
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and can be discreetly administered [13]. A
previous study noted patient satisfaction with
V-Go stating it was simple to use, discreet, and
comfortable to wear [11].
V-Go is indicated for any adult patient
requiring insulin regardless of type of diabetes
or use of concomitant anti-hyperglycemic
medications. V-Go delivers a consistent and
continuous basal insulin rate over a 24 h period,
which may offer improved efficiency over
subcutaneous basal injections. The on-demand
bolus dosing feature may ease the transition to
basal-bolus therapy when mealtime insulin is
required in patients prescribed a basal only
regimen or those naı¨ve to insulin. Furthermore,
in patients using MDI, the ability to deliver
mealtime insulin as needed without an
additional injection may facilitate patients
getting the insulin they need to improve their
glycemic control.
Fear of hypoglycemia has been reported as a
reason patients delay starting insulin therapy
[20] but in this study there was no difference in
patient-reported hypoglycemia after switching
to insulin therapy with V-Go. Fear of weight
gain has been reported as another reason for
delay in treatment intensification [20]. Patients
in the study saw a mean increase in weight of
only 1.5 kg from baseline to 27 weeks after
switching to V-Go. Although the prescribed
dose of insulin decreased, patients were likely
administering their insulin more appropriately
enabling a more efficient cellular uptake of
glucose resulting in rehydration and weight
gain. This change in weight was well-within
what is expected with insulin therapy, and
although the change was statistically
significant, it was not clinically relevant.
Varying titration practices across clinicians
in our centers could have impacted study
Table 3 Clinical measures at baseline and on V-Go based on change in concomitant anti-hyperglycemic medications











Baseline 9.48 (9.22–9.74) 10.04 (9.62–10.46) 9.35 (8.91–9.79)
On V-Go 8.09 (7.83–8.35) 8.08 (7.66–8.50) 8.03 (7.59–8.47)
Insulin TDD (U/day)
Baseline 80 (74–86) 112* (102–123) 65 (54–77)
On V-Go 56 (50–62) 68 (58–78) 53 (43–64)
Weight (kg)
Baseline 93 (89–97) 105* (99–111) 93 (87–100)
On V-Go 94 (90–98) 107* (101–114) 95 (89–102)
Data are least-squares mean with corresponding 95% conﬁdence intervals derived from a repeated measures mixed model
based on 14-week results. Baseline insulin TDD reﬂects prescribed lower limit TDD. Only those changes in concomitant
anti-hyperglycemic medication(s) providing sufﬁcient time for clinical effect were categorized as an increase or decrease
HbA1c glycated hemoglobin, TDD total daily dose
* P\0.01 compared to same measure for both no change and decrease in concomitant anti-hyperglycemic medication(s)
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results. The majority of titration that occurred
was related to mealtime bolus dosing; however,
no titration of bolus dosages occurred in
approximately 50% of patients. It is likely that
even greater reductions in HbA1c could have
been achieved with additional insulin titration.
The V-Go insulin delivery device delivers a
maximum of 76 units/day. In the current study,
V-Go adequately met the insulin requirements
of over 90% of study patients without the need
for supplemental insulin, which is clinically
significant considering the study included
patients prescribed a range of insulin up to
310 units per day at baseline.
Study outcomes were analyzed according to
subsets of patients who had an increase, a
decrease, or no change to concomitant
anti-hyperglycemic medications. The analysis
showed that patients with an increase in
concomitant medications weighed
significantly more and were prescribed a
higher TDD of insulin prior to V-Go use than
those patients with no change or a medication
decrease. This is not surprising, as higher
insulin doses are typically prescribed in
patients with increased body weight, and it is
reasonable to escalate treatment with an
additional medication in patients already
receiving a high TDD of insulin. After
14 weeks on V-Go patients with an increase in
concomitant medication continued to have a
significantly higher weight; however, there was
no difference in TDD of insulin used with V-Go
between patients with an increase in
medications and patients with a decrease or
no change in concomitant medications.
Additionally, all patients had a similar
decrease in HbA1c regardless of concomitant
medication status, which supports the
conclusion that the addition or removal of
concomitant medications did not impact the
effectiveness of V-Go.
There are several limitations in our current
investigation. The study was a retrospective
database analysis and the current analysis did
not include a parallel control group. The
baseline data of the study group served as the
control comparison and a systematic and
careful review was performed to identify
patients switched to V-Go to ensure there was
no sample selection bias. Additionally, there
were no educational initiatives or practice
changes implemented during the study
timeframe that could have contributed to
improvement of glycemic control after
patients switched to V-Go. To be included in
the analysis, patients were required to have at
least one follow-up office visit with an HbA1c
result recorded so the data in our study may not
be representative of all patients initiating V-Go
therapy as discontinuation prior to a follow-up
HbA1c was possible. Additionally, at the close of
the analysis period 35 of the patients included
had not returned for a second follow-up visit
and, therefore, it is unknown whether or not
they remained on V-Go after the first follow-up
visit. Frequency of patient contact, forced
insulin titration, and strict patient and
practice adherence measures were not
enforced, which reflects real-world diabetes
management and standard of care. This may
be considered a limitation as greater reductions
in HbA1c may have been possible with
additional patient contact and titrations, both
in the study patients and as a standard of care.
Analysis of insulin use relied on the prescribed
ranges and patient reported use available in
medical records; actual patient use may have
differed. Hypoglycemia was self-reported by
patients and recorded in medical records. In
our experience, patients report any clinically
relevant hypoglycemic event during their office
visits, and events reported by patients are
consistently recorded in medical records. No
Diabetes Ther (2015) 6:531–545 543
change in data recording process was made
during the study timeframe, so these data
limitations were consistent across baseline and
V-Go visits and are not felt to have impacted the
study conclusions.
CONCLUSIONS
Our study supports the safety and effectiveness
of V-Go in improving glycemic control in
patients with sub-optimally controlled diabetes
requiring insulin. V-Go is an appropriate
therapy for a broad range of patients;
statistically significant reductions in HbA1c
were seen with V-Go use in all subsets of
patients including type 2, type 1/LADA, naı¨ve
to insulin, and patients administering insulin
prior to V-Go. Reports of hypoglycemia were
similar prior to and after switching to V-Go.
Patients administering insulin at baseline
experienced substantial decreases in HbA1c
while requiring a lower TDD of insulin. V-Go
offers an efficient and efficacious method of
insulin delivery that can enhance patient
compliance and optimize glycemic control.
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